Results 41 to 50 of about 113,823 (359)
Establishment of Care System for Hemophilia in China: Current Status and Future Prospect
罕见病研究, 2022 Hemophilia is a X-linked recessive hereditary bleeding disorders. The patients need to receive replacement treatment with coagulation factors in their whole lives.
YANG Renchi
doaj +1 more source
Haematologica, 2016 Recent evidence suggests that patients with severe hemophilia B may have a less severe disease compared to severe hemophilia A. To investigate clinical, radiological, laboratory and histological differences in the arthropathy of severe hemophilia A and ...
Daniela Melchiorre +9 more
doaj +1 more source
Endothelial cells derived from patients' induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A. [PDF]
, 2020 Hemophilia A (HA) is a bleeding disorder characterized by spontaneous and prolonged hemorrhage. The disease is caused by mutations in the coagulation factor 8 gene (F8) leading to factor VIII (FVIII) deficiency.
Agu, Emmanuel +9 more
core +1 more source
Current Situation and Prospect of Pharmacoeconomic Evaluation of Hemophilia in China
罕见病研究, 2022 In 2018, hemophilia, one of the first ones, entered into the catalogue of Rare Disease in China. However, drug accessibility and affordability have been the challenges for hemophilia patients.
LI Shunping, DOU Lei, FANG Yunhai
doaj +1 more source
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. [PDF]
, 2001 Long-term expression of coagulation factor IX (FIX) has been observed in murine and canine models following administration of recombinant adeno-associated viral (rAAV) vectors into either the portal vein or muscle. These studies were designed to evaluate
Davidoff, A +5 more
core +1 more source
Hemophilia therapy: the future has begun
Haematologica, 2020 The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B ...
P. Mannucci
semanticscholar +1 more source
Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
Seminars in Thrombosis and Hemostasis, 2022 Accurate measurement of clotting factors VIII (FVIII) or IX (FIX) is vital for comprehensive diagnosis and management of patients with hemophilia A or B. The one-stage activated partial thromboplastin time (aPTT)-based clotting assay is the most commonly
A. Bowyer, R. Gosselin
semanticscholar +1 more source
Joint status of patients with nonsevere hemophilia A
Journal of Thrombosis and Haemostasis, 2022 Joint bleeding in hemophilia may eventually lead to joint damage. In nonsevere hemophilia, joint bleeds occur infrequently. Currently, knowledge on the joint status of patients with nonsevere hemophilia using objective imaging is limited.
A. Zwagemaker +11 more
semanticscholar +1 more source
Experimental Biology and Medicine, 1931 Vines, 1 in 1920, while treating a patient with hemophilia observed that following the development of a local skin reaction to horse serum, not only did the bleeding cease, but there was also a reduction in the coagulation time of the capillary blood. In 1926, Mills 2 repeated the observations of Vines.
openaire +3 more sources
Porcine model of hemophilia A. [PDF]
PLoS ONE, 2012 Hemophilia A is a common X chromosome-linked genetic bleeding disorder caused by abnormalities in the coagulation factor VIII gene (F8). Hemophilia A patients suffer from a bleeding diathesis, such as life-threatening bleeding in the brain and harmful ...
Yuji Kashiwakura +15 more
doaj +1 more source